HhAntag

CAS No. 496794-70-8

HhAntag( HhAntag | Hh-Antag | Hh Antag )

Catalog No. M17525 CAS No. 496794-70-8

HhAntag is a small molecule inhibitor of GLI1-mediated transcription, an essential down-stream element of the Hedgehog (Hh) pathway with the anti-tumor activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 102 In Stock
5MG 185 In Stock
10MG 320 In Stock
25MG 529 In Stock
50MG 771 In Stock
100MG 1062 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    HhAntag
  • Note
    Research use only, not for human use.
  • Brief Description
    HhAntag is a small molecule inhibitor of GLI1-mediated transcription, an essential down-stream element of the Hedgehog (Hh) pathway with the anti-tumor activity.
  • Description
    HhAntag is a GLI1-mediated transcription inhibitor. It acts as an inhibitor of the Shh pathway.
  • In Vitro
    HhAntag (2-30 μM; 72?hours) demonstrates to be?10-times more potent than the natural product SMO antagonist, cyclopamine, at inhibiting Hh pathway activity and it inhibits Hh signalling pathway sensitivitive cells with IC50 values ranging from 2?μM to >30?μM.HhAntag inhibits AsPC-1, BXPC-3, CFPAC, HPAC, HPAF-II, KP4, Panc 03.27, PA-TU-8902, PSN-1, SU.86.86 cells with IC50 values of 30 μM, 5.4 μM, 5.8 μM, 2.7 μM, 6.2 μM,10.3 μM, 2.5 μM, 2.9 μM, 5.8 μM and 2.7 μM, respectively.HhAntag (100 nM) is needed to completely inhibit Hh signalling in a Hh-responsive human mesenchymal cell line (HEPM) expressing a?GLI?luciferase reporter construct (HEPM-rep), the IC50?of 5?nM 400-times lower than that required to inhibit cell growth by 50% in the most sensitive cancer cell line (1.9?μM).
  • In Vivo
    HhAntag (oral administraion; 75 mg/kg or 100 mg/kg; twice daily; 25 days) results in significant growth delay in HT55 and HT-29 colorectal cell line xenografts models, with average tumour growth inhibitions of 29% and 48%, respectively. Whereas HhAntag had no effect on the growth of DLD-1 xenografts. Animal Model:Primary human xenografts?in?female CD1 nu/nu mice of 6–8?weeks (DLD-1, HT55 and HT-29 cells)Dosage:75 mg/kg or 100 mg/kg Administration:Oral administraion; twice daily; 25 days Result:Resulted in growth delay of HT55 and HT-29 xenografts, but had no effects on DLD-1 xenografts.
  • Synonyms
    HhAntag | Hh-Antag | Hh Antag
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    TRP/TRPV Channel
  • Recptor
    Gli
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    496794-70-8
  • Formula Weight
    450.92
  • Molecular Formula
    C24H23ClN4O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 100 mg/mL. 221.77 mM; H2O : < 0.1 mg/mL
  • SMILES
    C(=O)(c1cc(cc(c1)OC)OC)Nc1cc(c(cc1)Cl)c1nc2c([nH]1)cc(cc2)N(C)C
  • Chemical Name
    N-[4-Chloro-3-[6-(dimethylamino)-1H-benzimidazol-2-yl]phenyl]-3,5-dimethoxybenzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Actis, Marcelo; Connelly, Michele C.; Mayasundari, Anand et al. Biopolymers (2011), 95(1), 24-30.
molnova catalog
related products
  • GSK2193874

    GSK2193874 was identified as a selective orally active TRPV4 blocker.

  • Pellitorine

    Pellitorine is an extract of Tetradium daniellii, and acts as a TRPV1 antagonist.

  • MK-2295

    MK-2295 is a potent TRPV1 antagonist. MK-2295 can be used in studies about the treatment of chronic pain.